MORE►
Charles River Laboratories International
Left: Daniel Hargrove, co-founder and CEO of InterAct Therapeutics; Right: Isaac Chan, MD, PhD, Co-founder and CSO of InterAct Therapeutics [Photos: LinkedIn]
UTSW Spinout InterAct Therapeutics Selected by Cell & Gene Therapy Incubator Program
by Sandra Engelland | Dec 11, 2025
InterAct, which launched inside BioLabs at Pegasus Park, is a preclinical stage biotech company developing AAV8-based gene therapies for metastatic cancer, with an initial focus on breast cancer-derived liver metastases.
by Kevin Cummings |
Oct 18, 2022
Dallas-based Nanoscope Therapeutics is accelerating the development of therapies that could restore sight in patients with the help of a publicly traded firm. The retinal degenerative diseases-focused biotech company announced a new gene therapy manufacturing partnership with contract research organization Charles River Laboratories International.
MORE►
